StartsideFTRE • NASDAQ
add
Fortrea Holdings Inc
19,73 $
Etterbørs:(0,00 %)0,00
19,73 $
Stengt: 22. nov., 16:16:10 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Forrige sluttkurs
19,50 $
Dagsintervall
19,18 $ - 20,14 $
Årsintervall
16,53 $ - 41,02 $
Markedsverdi
1,77 mrd. USD
Gjennomsnittlig volum
1,32 mill.
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD) | sep. 2024info | Endring år til år |
---|---|---|
Omsetning | 674,90 mill. | −5,45 % |
Driftskostnader | 157,50 mill. | 21,53 % |
Nettoomsetning | −27,90 mill. | −99,29 % |
Netto resultatmargin | −4,13 | −110,71 % |
Fortjeneste per aksje | 0,23 | −4,17 % |
EBITDA | 12,00 mill. | −72,22 % |
Faktisk avgiftssats | 48,32 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(USD) | sep. 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 105,30 mill. | −4,01 % |
Totale aktiva | 3,66 mrd. | −15,13 % |
Totale passiva | 2,15 mrd. | −18,01 % |
Total egenkapital | 1,51 mrd. | — |
Utestående aksjer | 89,70 mill. | — |
P/B-forhold | 1,16 | — |
Avkastning på aktiva | −0,64 % | — |
Avkastning på kapital | −0,85 % | — |
Kontantstrøm
Netto kontantstrøm
(USD) | sep. 2024info | Endring år til år |
---|---|---|
Nettoomsetning | −27,90 mill. | −99,29 % |
Kontantstrøm fra drift | −2,40 mill. | −226,32 % |
Kontanter fra investering | −8,10 mill. | −400,00 % |
Kontanter fra finansiering | −14,00 mill. | −81,82 % |
Netto kontantstrøm | −20,90 mill. | −309,80 % |
Fri kontantstrøm | −19,35 mill. | −269,37 % |
Om
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Administrerende direktør
Grunnlagt
apr. 1996
Nettsted
Ansatte
15 500